NLA

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings

Retrieved on: 
火曜日, 5月 21, 2024
Patient, Cardiovascular disease, Primate, EAS, Hypercholesterolemia, Risk, NLA, NAMS, Congress, Biomarker, Adipose tissue, National Lipid Association

NAARDEN, the Netherlands and MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 92nd Congress and the National Lipid Association (NLA) 2024 Scientific Sessions, taking place on May 26 – 29 in Lyon, France and May 30 – June 2 in Las Vegas, Nevada, respectively.

Key Points: 
  • -- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers --
    NAARDEN, the Netherlands and MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 92nd Congress and the National Lipid Association (NLA) 2024 Scientific Sessions, taking place on May 26 – 29 in Lyon, France and May 30 – June 2 in Las Vegas, Nevada, respectively.
  • Presentation details are as follows:
    Oral Presentation Session Date and Time: Monday, May 27, 2024, 2:42 PM- 2:49 PM CET (8:42 AM-8:49 AM ET)
    Oral Presentation Session Date and Time: Tuesday, May 28, 2024, 2:12 PM- 2:19 PM CET (8:12 AM-8:19 AM ET)
    Oral Presentation Session Date and Time: Tuesday, May 28, 2024, 3:17-3:24 CET (9:17 AM-9:24 AM ET)
    Oral Presentation Session Date and Time: Tuesday, May 28, 2024, 3:24-3:31 CET (9:24 AM-9:31 AM ET)
    Title: Obicetrapib does not Accumulate in Adipose Tissue: Results from Studies in Man and Non-Human Primates
    Title: Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates Abstract/Poster #: 127

Skyhigh Security Announces New AI Innovations at RSA Conference 2024

Retrieved on: 
水曜日, 5月 8, 2024
Data Management, Security, Technology, Software, Artificial Intelligence, Internet, Cloud, Completeness, AI, Library, API, Product management, Organization, VPN, Control, Sky High, Private Access, Security Service, IP, RSA Conference, Conference, NLA, CASB, Critical, Incident management, Risk assessment, SAP S/4HANA, ChatGPT, Publication, SWG, Research, Procore, SAP, Policy, Magic, Moscone Center, LLM, History, Gen, DLP, Visibility, Virtual private network, RSAC, Magic Quadrant, Medical device

RSAC 2024 – Today, Skyhigh Security announced strategic additions to its Security Service Edge (SSE) portfolio at RSA Conference (RSAC) 2024 .

Key Points: 
  • RSAC 2024 – Today, Skyhigh Security announced strategic additions to its Security Service Edge (SSE) portfolio at RSA Conference (RSAC) 2024 .
  • RSAC attendees can meet with Skyhigh Security at the Moscone Center in San Francisco at booth #N-5378.
  • Its Skyhigh Security Service Edge (SSE) portfolio is currently trusted by over 3,000 global customers, including eight out of 10 of the world’s largest banks.
  • New AI innovations to the Skyhigh SSE portfolio include:
    Deep Visibility and Risk Assessment for AI Apps: Skyhigh Cloud Access Security Broker (CASB) innovations around AI visibility and risk assessment include support for AI sub-categories, Large Language Model (LLM) attributes, and deep risk assessment around LLM model security using red teaming.

RioCan Reports First Quarter Results - Strong Leasing Results Driven by Accelerated Demand for High-Quality RioCan Space

Retrieved on: 
火曜日, 5月 7, 2024
Commercial Building & Real Estate, Construction & Property, REIT, Phase 10, NLA, The, Trust, Acquisition, Security (finance)

During the First Quarter, $62.9 million or 54,000 square feet of properties under development were transferred to income producing properties.

Key Points: 
  • During the First Quarter, $62.9 million or 54,000 square feet of properties under development were transferred to income producing properties.
  • The retail component is 94% leased, with more than half of the space open and operating.
  • As market conditions permit, RioCan provides mezzanine financing, earning interest income at attractive rates relative to its cost of capital.
  • During Q1 2024, RioCan issued $68.0 million of new loans and $30.6 million of existing loans were repaid.

runZero Research Explores Unexpected Exposures in Enterprise Infrastructure

Retrieved on: 
火曜日, 5月 7, 2024
Technology, Mobile, Wireless, Security, Other Technology, Software, Internet, IOT (Internet of Things), Data Management, Artificial Intelligence, OpenSSL, VMware ESXi, Risk, ICS, SMB, Publication, RSA Conference, RDP, TLS, Ubuntu, Conference, Research, Remote Desktop Protocol, VMware, NLA, Server Message Block, Behavior, SSH, Organization, H. D. Moore, Secure Shell, Risk management

As a leading provider of Cyber Asset Attack Surface Management (CAASM), this report leverages runZero’s unique perspective across hundreds of enterprise networks, including internal infrastructure, internet-facing assets, and cloud environments.

Key Points: 
  • As a leading provider of Cyber Asset Attack Surface Management (CAASM), this report leverages runZero’s unique perspective across hundreds of enterprise networks, including internal infrastructure, internet-facing assets, and cloud environments.
  • “Our research reveals alarming gaps and unexpected trends in enterprise infrastructure, including the decay of network segmentation, persistent challenges in attack surface management, and the increasing volume of dark matter on modern networks,” said HD Moore, founder and CEO.
  • These assets include programmable logic controllers, power meters, and protocol gateways, all of which play an important role in critical infrastructure.
  • runZero identified unexpected IP-forwarding behavior across dozens of device types, ranging from smart TVs to robotic vacuum cleaners.

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

Retrieved on: 
月曜日, 4月 29, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Bank of America, Congress, DEEP, ATS, Arrowhead, Antiviral Research, RESULTS, Conference, Asthma, EAS, NLA, National Lipid Association, AN, American Thoracic Society

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
    2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024
    BofA Securities 2024 Healthcare Conference – May 13-16, 2024
    TIDES USA 2024 – May 14-17, 2024
    American Thoracic Society (ATS) 2024 International Conference – May 17-22, 2024
    Title: A First-in-Human Study of ARO-RAGE, a Novel Inhaled RNA-Interference Therapy for Asthma
    37th International Conference on Antiviral Research (ICAR2024) – May 20-24, 2024
    European Atherosclerosis Society (EAS) 92nd Congress – May 26-29, 2024
    Title: PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Title: ZODASIRAN SILENCES HEPATIC ANGPTL3 LEADING TO DEEP AND DURABLE REDUCTIONS IN ATHEROGENIC LIPIDS AND LIPOPROTEINS IN MIXED DYSLIPIDEMIA PATIENTS: FINAL RESULTS FROM ARCHES-2, DOUBLE-BLIND PERIOD
    2024 National Lipid Association (NLA) Scientific Sessions – May 30 – June 2, 2024
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Expro Group Holdings N.V. Announces First Quarter 2024 Results

Retrieved on: 
木曜日, 4月 25, 2024
Alternative Energy, Energy, Other Energy, Oil, Gas, Well, Rotation, Central Time, Net, ESSA, Risk, Safety, Integrity, Natural gas, Carbon, Segment, CCUS, Public expenditure, NLA, Tax, DNB ASA, Acquisition, Movement, GAAP, Airline

Expro Group Holdings N.V. (NYSE: XPRO) (the “Company” or “Expro”) today reported financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • Expro Group Holdings N.V. (NYSE: XPRO) (the “Company” or “Expro”) today reported financial and operational results for the three months ended March 31, 2024.
  • Adjusted EBITDA margin for the first quarter of 2024 and the fourth quarter of 2023 was 18% and 21%, respectively.
  • Unless otherwise noted, the following discussion compares the quarterly results for the first quarter of 2024 to the results for the fourth quarter of 2023.
  • The Company will host a conference call to discuss first quarter 2024 results on Thursday, April 25, 2024, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time).

A United Front, the Wounded Warriors Family Support partners with the Young Marines National Foundation

Retrieved on: 
水曜日, 3月 27, 2024
RET, Mentorship, Veteran, Partnership, NLA, Family, Capitol, Woman, Tanzania Military Academy, Trustee, Young Marines, Management

DUMFRIES, Va., March 27, 2024 /PRNewswire-PRWeb/ -- Together, we are stronger. That's the underlying principle as two benevolent forces supporting Young Marines and Veteran families—Wounded Warriors Family Support and Young Marines National Foundation—unite in an unprecedented partnership.

Key Points: 
  • With the support of Wounded Warriors Family Support, the Young Marines National Foundation donated $128,000 to the Young Marines, a national youth organization, to support the 2024 National Leadership Academy
    DUMFRIES, Va., March 27, 2024 /PRNewswire-PRWeb/ -- Together, we are stronger.
  • That's the underlying principle as two benevolent forces supporting Young Marines and Veteran families—Wounded Warriors Family Support and Young Marines National Foundation—unite in an unprecedented partnership.
  • With the support of Wounded Warriors Family Support, the Young Marines National Foundation (YMNF) donated $128,000 to the Young Marines, a national youth organization, to support the 2024 National Leadership Academy (NLA) and efforts to teach kids the value of selfless service and honoring veterans.
  • "The Young Marines is exceptionally grateful to receive the support from Wounded Warrior Family Support and the Young Marines National Foundation," said Col Davis.

Next Level Aviation® Appoints Rick Stine to Its Board of Directors

Retrieved on: 
火曜日, 3月 26, 2024
HEICO, Component, NLA, USM, NASA, StandardAero, Aviation, Next Level, Management

"Rick" Stine as the newest addition to its Board of Directors.

Key Points: 
  • "Rick" Stine as the newest addition to its Board of Directors.
  • As Director, Mr. Stine will collaborate closely with senior management and the Board to help shape and execute Next Level Aviation®'s strategic growth initiatives.
  • "The senior management team and Board are excited to work with Rick and leverage his commercial aviation aftermarket expertise to expand Next Level Aviation's global footprint in the years ahead."
  • New Next Level Aviation® Director Rick Stine commented, "I'm thrilled to join Next Level Aviation®'s Board of Directors.

Next Level Aviation® Appoints Rick Stine to Its Board of Directors

Retrieved on: 
火曜日, 3月 26, 2024
HEICO, Component, NLA, USM, NASA, StandardAero, Aviation, Next Level, Management

"Rick" Stine as the newest addition to its Board of Directors.

Key Points: 
  • "Rick" Stine as the newest addition to its Board of Directors.
  • As Director, Mr. Stine will collaborate closely with senior management and the Board to help shape and execute Next Level Aviation®'s strategic growth initiatives.
  • "The senior management team and Board are excited to work with Rick and leverage his commercial aviation aftermarket expertise to expand Next Level Aviation's global footprint in the years ahead."
  • New Next Level Aviation® Director Rick Stine commented, "I'm thrilled to join Next Level Aviation®'s Board of Directors.

Expro Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
水曜日, 2月 21, 2024
Alternative Energy, Energy, Other Energy, Oil, Gas, Well, Depreciation, MENA, Fashion show, Intervention, Continental shelf, Tax, PRT, Segment, GAAP, LWI, Central Time, Integrity, Partnership, TRS, Carbon, Safety, Public expenditure, Kingdom, Acquisition, ESSA, Risk, NLA

Net cash provided by operating activities for the fourth quarter of 2023 was $33 million compared to net cash provided by operating activities of $59 million for the third quarter of 2023.

Key Points: 
  • Net cash provided by operating activities for the fourth quarter of 2023 was $33 million compared to net cash provided by operating activities of $59 million for the third quarter of 2023.
  • Adjusted cash flow from operations1 for the fourth quarter of 2023 was $43 million compared to $64 million for the third quarter of 2023.
  • Unless otherwise noted, the following discussion compares the quarterly results for the fourth quarter of 2023 to the results for the third quarter of 2023.
  • Depreciation and amortization expense was $63 million for the fourth quarter of 2023 compared to $37 million for the third quarter of 2023.